Abstract
A DNA vaccine encoding PML-RAR alpha fusion gene is thought to be a promising approach for acute promyelocytic leukemia patients to enhance immune responses after attaining complete remission. In this study, we sought to enhance cellular immunity by coexpressing human interleukin (hIL)-2 genes. Successfully constructed plasmids PML-RAR alpha-hIL-2-pIRES, PML-RAR alpha-pIRES and hIL-2-pIRES were delivered intramuscularly in BALB/C mice at 14-day intervals for three cycles. The cellular immune responses with respect to the specific cytotoxicity of spleen cells; interferon-gamma secretion in sera, and the T-cell receptor rearrangement excision circles of thymocyte were significantly increased from PML-RARalpha-hIL-2-pIRES immunized mice. Our results indicate that a DNA vaccine with PML fusion gene segment and hIL-2 together might elicit increased cellular immune responses in mice.
Publication types
-
Research Support, Non-U.S. Gov't
MeSH terms
-
Animals
-
Cell Line, Tumor
-
Cytotoxicity Tests, Immunologic
-
Gene Rearrangement, T-Lymphocyte
-
Genetic Vectors / administration & dosage
-
Humans
-
Immunity, Cellular*
-
Immunization
-
Injections, Intramuscular
-
Interferon-gamma / metabolism
-
Interleukin-2 / genetics
-
Interleukin-2 / immunology*
-
Male
-
Mice
-
Mice, Inbred BALB C
-
Muscle, Skeletal / immunology
-
Muscle, Skeletal / ultrastructure
-
Oncogene Proteins, Fusion / genetics
-
Oncogene Proteins, Fusion / immunology*
-
Random Allocation
-
Recombinant Fusion Proteins / genetics
-
Recombinant Fusion Proteins / immunology
-
Spleen / cytology
-
Spleen / immunology
-
T-Lymphocytes, Cytotoxic / immunology
-
Vaccines, DNA / administration & dosage
-
Vaccines, DNA / immunology*
Substances
-
Interleukin-2
-
Oncogene Proteins, Fusion
-
Recombinant Fusion Proteins
-
Vaccines, DNA
-
promyelocytic leukemia-retinoic acid receptor alpha fusion oncoprotein
-
Interferon-gamma